Breakthrough Publication: Leading Hospitals Present First Data from Successful Customer Evaluations of FASTinov® Technology

Breakthrough Publication: Leading Hospitals Present First Data from Successful Customer Evaluations of FASTinov® Technology

September 27th 2023

(Porto, Portugal) – FASTinov, the global leader in rapid antimicrobial susceptibility testing (AST), is excited to announce the publication of groundbreaking data from the very first customer evaluations of its FASTinov® technology. The study, presented at the ENAI 2023 event in Porto, Portugal, showcases the remarkable success of FASTinov® in real hospital environments, marking a significant milestone in the field of infectious disease management.

The data, derived from customer evaluations conducted at Centro Hospitalar Universitário de Coimbra and Hospital Garcia de Orta in Almada, represents the culmination of extensive research and collaboration between FASTinov and leading healthcare institutions. This pioneering study provides compelling evidence that FASTinov® technology can be seamlessly integrated into hospital workflows, delivering ultra-rapid AST results within approximately 2 hours.

Key findings from the publication include:

– FASTinov® kits accurately provide ultra-rapid AST (~2h), demonstrating the feasibility of real-time antimicrobial susceptibility testing in hospital settings.

– FASTinov sample preparation can be readily used for MALDI TOF-based ID, offering a time-saving combination of consistent identification with precise results.

– 100% of susceptibility reports from FASTgramneg and FASTgrampos kits were provided in the same shift, highlighting the efficiency and reliability of FASTINOVinov’s technology.

Dr. Cidália Pina Vaz, Chief Scientific Officer of FASTinov, expressed her enthusiasm for the publication of these groundbreaking results.
“The publication of this data is a testament to the effectiveness and reliability of FASTinov® technology in real hospital environments. We are proud to demonstrate that our AST solution can deliver timely and accurate results, empowering healthcare professionals to make informed treatment decisions and improve patient outcomes.”

Nuno Afonso, CEO of FASTinov, highlighted the significance of this achievement in advancing the field of infectious disease management.
“This publication represents a major milestone for FASTinov and the healthcare industry as a whole. By demonstrating the feasibility and efficacy of ultra-rapid AST in real-world settings, we are paving the way for a new era in infectious disease diagnostics.”

As FASTinov continues to lead the way in rapid AST technology, the publication of this groundbreaking data underscores its commitment to innovation and excellence in healthcare.

About FASTinov

FASTinov is a leading innovator in rapid antimicrobial susceptibility testing, dedicated to revolutionizing patient care in sepsis contexts. With a mission to provide actionable same-shift results, FASTinov’s cutting-edge technology offers healthcare professionals unprecedented insights for targeted treatment decisions.

Share with friends